Abstract
A new method with a low pH step to dissociate serum complexes has been developed to measure serum levels of antigens associated with ovarian cancer. The antigens are detected by monoclonal antibodies HMFG1 and HMFG2 and have been compared to an existing ovarian cancer associated antigen detected by the antibody CA125. Elevated HMFG1 was found in 56%, and elevated HMFG2 in 65% of 924 sera from 85 patients with ovarian cancer. CA125 was elevated in 85% of these sera. When the three markers were used in conjunction, 95% of sera from patients with ovarian cancer were positive--compared with 7% in sera from healthy control subjects. Therefore, the combination of HMFG1, HMFG2 and CA125 increases the diagnostic accuracy. If all three markers are normal in a patient previously treated for ovarian cancer then no further positive information regarding disease status can be obtained by ultrasound and CT scanning.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arklie J., Taylor-Papadimitrious J., Bodmer W., Egan M., Millis R. Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers. Int J Cancer. 1981 Jul 15;28(1):23–29. doi: 10.1002/ijc.2910280105. [DOI] [PubMed] [Google Scholar]
- Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
- Canney P. A., Moore M., Wilkinson P. M., James R. D. Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer. 1984 Dec;50(6):765–769. doi: 10.1038/bjc.1984.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cohen C. J., Goldberg J. D., Holland J. F., Bruckner H. W., Deppe G., Gusberg S. B., Wallach R. C., Kabakow B., Rodin J. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO Stages III and IV) as measured by surgical end-staging (second-look operation). Am J Obstet Gynecol. 1983 Apr 15;145(8):955–967. doi: 10.1016/0002-9378(83)90849-9. [DOI] [PubMed] [Google Scholar]
- Dhokia B., Pectasides D., Self C., Habib N. A., Hershman M., Wood C. B., Munro A. J., Epenetos A. A. A low pH enzyme linked immunoassay using two monoclonal antibodies for the serological detection and monitoring of breast cancer. Br J Cancer. 1986 Dec;54(6):885–889. doi: 10.1038/bjc.1986.257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Doellgast G. J., Homesley H. D. Placental-type alkaline phosphatase in ovarian cancer fluids and tissues. Obstet Gynecol. 1984 Mar;63(3):324–329. [PubMed] [Google Scholar]
- Ishikawa E., Imagawa M., Hashida S., Yoshitake S., Hamaguchi Y., Ueno T. Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining. J Immunoassay. 1983;4(3):209–327. doi: 10.1080/15321818308057011. [DOI] [PubMed] [Google Scholar]
- Johnson R. J., Blackledge G., Eddleston B., Crowther D. Abdomino-pelvic computed tomography in the management of ovarian carcinoma. Radiology. 1983 Feb;146(2):447–452. doi: 10.1148/radiology.146.2.6849092. [DOI] [PubMed] [Google Scholar]
- Tucker D. F., Oliver R. T., Travers P., Bodmer W. F. Serum marker potential of placental alkaline phosphatase-like activity in testicular germ cell tumours evaluated by H17E2 monoclonal antibody assay. Br J Cancer. 1985 May;51(5):631–639. doi: 10.1038/bjc.1985.95. [DOI] [PMC free article] [PubMed] [Google Scholar]